A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

  • STATUS
    Recruiting
  • participants needed
    6
  • sponsor
    Genentech, Inc.
Send
Updated on 19 February 2024
See if I qualify
radiopharmaceuticals

Summary

The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of [18F]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.

Details
Condition Dementia, Dementia, Alzheimer's Disease, Alzheimer's Disease
Age 18years - 100years
Treatment [18F]GTP1
Clinical Study IdentifierNCT04394845
SponsorGenentech, Inc.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Healthy with no clinically relevant finding on physical examination at screening and prior to radiopharmaceutical administration
Female participants must be willing to avoid pregnancy and refrain from donating eggs during the treatment period and for 30 days after the final dose
Male participants with partners of childbearing potential must commit to the use of two methods of contraception for the study duration and 90 days after the last dose
Male participants must not donate sperm for the duration of the study and 90 days after the last dose
Participants must have both Japanese parents and all Japanese grandparents

Exclusion Criteria

Participants with any significant medical disorder or disease expected to interfere with the study
Current or prior history (within a six-month period) of exposure to nicotine products
History of drug or alcohol abuse within 12 months prior to screening
Prior participation in other research protocols or clinical care in the last year, such that radiation exposure combined with that from the present study exceeds an effective dose of 50 millisievert (mSv), the allowable annual limit for research participants as established by the US Federal Guidelines
Use of any prescription drugs, herbal supplements, within 4 weeks prior to initial dosing
Use of over the counter (OTC) medication, dietary supplements, or vitamins, within 2 weeks prior to initial dosing
Known hypersensitivity to any component of the formulation of [18F]GTP1 or related compounds
Major surgery, or donation or loss of 400 mL or more of blood within 4 weeks prior to initial dosing
History of immunodeficiency diseases, including positive human immunodeficiency virus (HIV) test
Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody
Women who are pregnant, lactating or breastfeeding
Unsuitable veins for repeated venipuncture
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

radiopharmaceuticals

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.